| Budget Amount *help |
¥17,810,000 (Direct Cost: ¥13,700,000、Indirect Cost: ¥4,110,000)
Fiscal Year 2012: ¥3,380,000 (Direct Cost: ¥2,600,000、Indirect Cost: ¥780,000)
Fiscal Year 2011: ¥6,760,000 (Direct Cost: ¥5,200,000、Indirect Cost: ¥1,560,000)
Fiscal Year 2010: ¥7,670,000 (Direct Cost: ¥5,900,000、Indirect Cost: ¥1,770,000)
|
|---|
| Research Abstract |
ST101 stimulates memory molecule, Ca2+/calmodulin-dependent protein kinase II (CaMKII) in the hippocampus. In the present study, we investigated whether chronic administration of the neurovascular regenerative compound, ST101 elicits long lasting ameliorating effects on brain functions and defined the molecular mechanism underlying their therapeutic effects in the neurodegenerative disorders. ST101 was now under investigation in Phase II clinical trial of U.S.A. We defined T type voltage-gated calcium channel as molecular target of ST101. We next introduced novel and potent derivative, SAK3 by using neuro2A cells overexpressing T type voltage-gated calcium channel. This is the first discovery of activators of T type voltage-gated calcium channel in the world. The most promising evidence in our studies is that T type calcium channel is novel therapeutic target of Alzheimer therapy to restore the neural networks in the neurodegenerative disorders.
|
